Article first published in the Guardian: https://www.theguardian.com/science/political-science/2016/oct/14/why-losing-the-european-medicines-agency-is-bad-news-for-patients-jobs-and-the-nhs
I’m old enough to remember John Major’s government like it was yesterday. I watched the Maastricht debates, and I’m prepared to admit I even read the treaty. I remember the troubles that John Major had navigating debates over Europe, and that one of his achievements, despite all those difficulties, was securing the location of the European Medicines Agency (EMA) in the UK.
Twenty years on, that success is being put at risk by another Conservative prime minister. Major complained about “the bastards” on his own side – now they’re running the show. Earlier this week, I led a debate in Westminster on the future of the EMA because we need to know about the government’s plans for medicines regulation following Brexit.
While the EMA wasn’t spoken about much during the EU referendum campaign, the NHS certainly was, and the UK’s relationship with the EMA is absolutely crucial to the NHS. Strangely enough, no minister from the Department for Exiting the EU was available for the debate – a health minister was left to field the questions.
For two decades, the EMA has overseen medicines regulation across Europe. Responsible for the scientific evaluation of human and veterinary medicines developed by pharmaceutical companies, it grants marketing authorisations across the 28 EU member states, as well as the countries of the European Economic Area (Iceland, Liechtenstein and Norway).
The EMA is tasked with ensuring that all medicines available on the EU market are safe, effective and of high quality. It also works to harmonise the approach of national regulatory bodies – like the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Located in London’s Canary Wharf, with around 900 highly-skilled staff, the EMA serves a market of over 500 million people across the EU, accounting for 25 per cent of all global pharmaceutical sales. On its own, the UK accounts for just 3 per cent.
Last week, the chancellor Philip Hammond said that no one voted for Brexit to make us poorer. Yet the impact of Brexit on the EMA could do just that. As Theresa May herself said in July, “It is hard to think of an industry of greater strategic importance to Britain than its pharmaceutical industry.” In 2015, the UK pharmaceutical industry was worth £12.7 billion. A quarter of the world’s top prescription medicines were discovered and developed in the UK.
And the pharmaceutical industry is the backbone of the broader life sciences sector, which has a turnover of more than £60bn a year. In 2014, it invested £4bn in research and development, more than any other sector, and it employs 220,000 people. In my constituency of Cambridge alone, there are over 160 life sciences companies, reinforcing the local knowledge economy and contributing outside of the region as well. Indeed, Cambridge is one of just a handful of UK cities making a net contribution to HM Treasury, thanks in no small part to its vibrant life sciences. Under Brexit, this is now at risk.
A hard Brexit would see the UK out of the single market and the European Economic Area. So for pharmaceuticals and life sciences, what would change? First, industry experts suggest we could see delays to the approval of new medicines. In Canada and Australia, where drugs are regulated nationally, new medicines come to market between six months and a year later than in the EU.
So if pharmaceutical companies have to apply separately to the UK’s MHRA to supply a drug in the UK, we could see patients denied faster access to new medicines. The MHRA may struggle to cope with the additional burden, leading to a slower, less efficient system. Pharmaceutical companies may forego the smaller UK market in favour of the much larger EU market. And smaller companies, often developing pioneering treatments, may not have the capacity to file multiple applications at once.
Second, there is likely to be a physical change. The EMA’s headquarters is expected to move elsewhere. Several EU member states have reportedly thrown their hats in the ring to host it – including Denmark, Ireland, Italy, Sweden and Spain. This may create a knock-on effect on future investment and relocation decisions by global and European pharmaceutical companies, further chipping away at the UK economy.
Finally, losing the EMA could lead to a significant brain drain. Not only would we potentially lose the 900 people currently employed by the agency, but we could lose experienced people working elsewhere in the pharmaceutical industry. For instance, any company that sells into the European Economic Area must have a “qualified person for pharmacovigilance” (QPPV), as well as a deputy. There are currently 1,299 QPPVs in the UK who would either have to leave the UK or lose their role.
Negotiations are of course ongoing, but it is crucial the government gets this right. We need to secure the closest possible relationship between the EMA and the MHRA, and their continued regulatory cooperation, because ensuring swift access to the newest treatments is essential to public health. We need the UK’s pharmaceutical industry to remain strong to deliver jobs and economic benefits across the country, and to stimulate companies researching revolutionary treatments. Get this wrong and treatments will slow down, drug prices will go up – and our NHS will foot the bill.
Daniel Zeichner proved he’s done his homework as they scored 9 out of 9 on Terrence Higgins Trust’s HIV and sexual health quiz.
At Labours autumn conference in Liverpool, Daniel Zeichner went back to school and put on his thinking cap by taking the test, “How HIV aware are you?”.
Daniel Zeichner MP has spoken out about the threat to science funding ahead of the Comprehensive Spending Review in a Parliamentary debate, calling for a commitment on science spending and warning a tipping point is being reached.
Back in 2010 the publicly funded science budget was ring-fenced and frozen but Britain's public spend on science is now the smallest of all the G8 nations.
In his speech Mr Zeichner mentioned the Cambridge based Babraham Research Institute, MRC Laboratory of Molecular Research in Cambridge, Gurdon Institute and Astra Zeneca, and warned that in each case, threats to future science funding put key research at risk.
Mr Zeichner quoted evidence from the Babraham Research Institute who recently warned: “the current level of funding will not sustain the UK’s existing science and research capability, whilst any reduction would be extremely damaging, and that world leading scientists will leave the UK for other countries.
Daniel Zeichner MP discovered how the Alzheimer’s Research UK Stem Cell Research Centre is playing a key role in the fight against dementia when he visited the Cambridge facility.
The £2m centre, based at the Gurdon Institute at the University of Cambridge, was opened this year by the Great Abington-based charity and brings together leading stem cell researchers from the University of Cambridge and UCL (University College London). Scientists at the centre are using groundbreaking techniques to unravel the causes of Alzheimer’s disease and test potential new treatments.
Alzheimer’s, the most common cause of dementia, leads to the loss of brain cells and impairs the brain’s ability to function properly. Early symptoms include problems with memory and thinking, but as the disease progresses, physical functions such as walking and even swallowing can be affected. There are currently no treatments capable of stopping or slowing the disease, and scientists at the Stem Cell Research Centre, backed by the UK’s leading dementia research charity, are working to address this problem.
During a tour of the centre, Mr Zeichner learned how skin cells donateSPB_6652d by volunteers with different forms of the disease play a crucial role in this research. Scientists at the centre transform these cells into networks of functioning nerve cells, allowing them to replicate the disease in a dish. These cells can then be used to study how the disease develops, as well as to screen compounds that may help fight the disease.
Mr Zeichner said:
"Too many people still think that dementia is an inevitable part of getting older - it isn't. We now know that it is a disease and that we will be able to treat it - and that's what the scientists at the Gurdon Institute in Cambridge are working on, with tremendous support from Alzheimer's Research UK. They showed me how skin cells can now be turned into stem cells which allows detailed research and testing of new treatments without the use of animal experiments. It is all extremely positive - but there is a cloud on the horizon: decisions are looming about future science funding in the Government's financial review next month. It is vital the the long-term political consensus on stable science-funding is maintained. 1in 3 children born this year will develop Alzheimer's. Dementia costs us over £26 billion a year. It is our greatest health threat . This vital research must not be put at risk."
Labour leadership hopeful Yvette Cooper MP has visited Microsoft Research with Daniel Zeichner MP.
She met Laboratory Director Andrew Blake and some of the 100+ researchers, engaged in computer science research at the lab to hear about their ground breaking work.
Leading figures from the Cambridge Medi-Tech sector met Labour Shadow Business and Health Ministers at Cambridge's first
Medi-Tech Summit, organised by Labour’s Entrepreneurs Network, which seeks to develop and enhance local business communities. The Network has been established by Shadow Business Secretary Chuka Umunna MP.
Cambridge Cleantech launch their manifesto for the next Government in
Westminster today – Cambridge Labour Parliamentary Candidate Daniel
Zeichner will attend the event and says that the sector is vital to the
next wave in the Cambridge phenomenon:
Labour Parliamentary Candidate Daniel Zeichner has cut the ribbon on Owlstone's new manufacturing facility on the Cambridge Science Park.
The Cambridge News asked me my views on the name for the new Cambridge railway station at the Science Park. Here's what I said: